Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KGB
|
|||
| Former ID |
DNCL002760
|
|||
| Drug Name |
Abagovomab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2/3 | [1], [2] | |
| Company |
Menarini
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ovarian carcinoma antigen CA125 (MUC16) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8265). | |||
| REF 2 | ClinicalTrials.gov (NCT00418574) Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients. U.S. National Institutes of Health. | |||
| REF 3 | Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.